Hoth Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological disorders, infectious diseases, and oncology. Its lead candidate, HT-001, is a topical therapeutic designed to treat chemotherapy-induced rash, enabling patients to continue their cancer treatments without painful side effects, and is currently advancing through Phase 2 trials. The company is also developing HT-KIT, an oncology drug targeting cancer treatments, alongside initiatives in obesity in partnership with the U.S. Department of Veterans Affairs. Hoth Therapeutics employs a patient-focused approach, leveraging strategic intellectual property expansion and AI to de-risk and accelerate its diversified pipeline. These efforts address unmet medical needs in oncology, dermatology, and metabolic disorders, positioning the company as an emerging player in biotechnology. Founded in 2017 and headquartered in New York, New York, Hoth Therapeutics continues to advance its portfolio of novel treatments.